Curcumin as an Adjuvant to Cancer Immunotherapy
The components of the immune system play a very sincere and crucial role in combating tumors. However, despite their firm efforts of elimination, tumor cells cleverly escape the surveillance process by adopting several immune evasion mechanisms. The conversion of immunogenicity of tumor microenviron...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.675923/full |
| _version_ | 1819148145671536640 |
|---|---|
| author | Silpita Paul Gaurisankar Sa |
| author_facet | Silpita Paul Gaurisankar Sa |
| author_sort | Silpita Paul |
| collection | DOAJ |
| description | The components of the immune system play a very sincere and crucial role in combating tumors. However, despite their firm efforts of elimination, tumor cells cleverly escape the surveillance process by adopting several immune evasion mechanisms. The conversion of immunogenicity of tumor microenvironment into tolerogenic is considered as a prime reason for tumor immune escape. Therapeutically, different immunotherapies have been adopted to block such immune escaping routes along with better clinical outcomes. Still, the therapies are haunted by several drawbacks. Over time, curcumin has been considered as a potential anti-cancer molecule. Its potentialities have been recorded against the standard hallmarks of cancer such as continuous proliferation, escaping apoptosis, continuous angiogenesis, insensitivity to growth inhibitors, tissue invasion, and metastasis. Hence, the diversity of curcumin functioning has already been established and exploration of its application with immunotherapies might open up a new avenue for scientists and clinicians. In this review, we briefly discuss the tumor’s way of immune escaping, followed by various modern immunotherapies that have been used to encounter the escaping paths and their minute flaws. Finally, the conclusion has been drawn with the application of curcumin as a potential immune-adjuvant, which fearlessly could be used with immunotherapies for best outcomes. |
| first_indexed | 2024-12-22T13:41:04Z |
| format | Article |
| id | doaj.art-dfdc858862eb413ba23e0220aa5f626d |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-22T13:41:04Z |
| publishDate | 2021-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-dfdc858862eb413ba23e0220aa5f626d2022-12-21T18:23:56ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-08-011110.3389/fonc.2021.675923675923Curcumin as an Adjuvant to Cancer ImmunotherapySilpita PaulGaurisankar SaThe components of the immune system play a very sincere and crucial role in combating tumors. However, despite their firm efforts of elimination, tumor cells cleverly escape the surveillance process by adopting several immune evasion mechanisms. The conversion of immunogenicity of tumor microenvironment into tolerogenic is considered as a prime reason for tumor immune escape. Therapeutically, different immunotherapies have been adopted to block such immune escaping routes along with better clinical outcomes. Still, the therapies are haunted by several drawbacks. Over time, curcumin has been considered as a potential anti-cancer molecule. Its potentialities have been recorded against the standard hallmarks of cancer such as continuous proliferation, escaping apoptosis, continuous angiogenesis, insensitivity to growth inhibitors, tissue invasion, and metastasis. Hence, the diversity of curcumin functioning has already been established and exploration of its application with immunotherapies might open up a new avenue for scientists and clinicians. In this review, we briefly discuss the tumor’s way of immune escaping, followed by various modern immunotherapies that have been used to encounter the escaping paths and their minute flaws. Finally, the conclusion has been drawn with the application of curcumin as a potential immune-adjuvant, which fearlessly could be used with immunotherapies for best outcomes.https://www.frontiersin.org/articles/10.3389/fonc.2021.675923/fullcurcumindendritic cellCTLA4PD1/PD-L1immune cellsTreg cells |
| spellingShingle | Silpita Paul Gaurisankar Sa Curcumin as an Adjuvant to Cancer Immunotherapy Frontiers in Oncology curcumin dendritic cell CTLA4 PD1/PD-L1 immune cells Treg cells |
| title | Curcumin as an Adjuvant to Cancer Immunotherapy |
| title_full | Curcumin as an Adjuvant to Cancer Immunotherapy |
| title_fullStr | Curcumin as an Adjuvant to Cancer Immunotherapy |
| title_full_unstemmed | Curcumin as an Adjuvant to Cancer Immunotherapy |
| title_short | Curcumin as an Adjuvant to Cancer Immunotherapy |
| title_sort | curcumin as an adjuvant to cancer immunotherapy |
| topic | curcumin dendritic cell CTLA4 PD1/PD-L1 immune cells Treg cells |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.675923/full |
| work_keys_str_mv | AT silpitapaul curcuminasanadjuvanttocancerimmunotherapy AT gaurisankarsa curcuminasanadjuvanttocancerimmunotherapy |